Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
Acquisitions · S-4
Mergers & Acquisitions
M&A Details · Industry · Urgent
M&A Deals · Breakdown
Denali Therapeutics Inc. has no acquisition track records yet.
M&A Deals · History
Denali Therapeutics Inc. has no acquisition track records yet.
Denali Therapeutics Inc. can't present any M&A detail analysis.
Try it with one of the Urgent M&A Deals by clicking "Details".
Try it with one of the Urgent M&A Deals by clicking "Details".
M&A Deals · Within Industry
Keep an eye on latest M&A deals done inside the Biotechnology Industry.
M&A Deals · Urgent
Act, dont react; Track the most urgent M&A deals across all industries
Details
Details
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
Details
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00